Evolution Research Group (ERG), an independent clinical research site company, with an expertise in early- and late-stage neuroscience drug development, has acquired Rochester, NY-based Finger Lakes Clinical Research (FLCR), a clinical research facility specializing in pediatric and adult central nervous system trials for major national and international pharmaceutical firms.

Founded and directed by Principal Investigator Sarah D. Atkinson, MD, FLCR has conducted trials across a broad range of illnesses, including anxiety disorders, ADHD, depression, bipolar disorder, schizophrenia and other mental illnesses since its founding in 2002. 

“We are very excited to welcome Dr. Atkinson and FLCR to the ERG family,” said Lori Wright, chief executive officer of ERG. “The addition of FLCR expands ERG’s geographic capabilities in both adult and pediatric outpatient trials and further enhances ERG’s growing service offerings to our clients.” Dr. Atkinson added, “My staff and I are delighted to be joining ERG. Its excellent reputation, high quality standards, clinical expertise, and strong business development capabilities, make ERG the ideal partner for FLCR in this next chapter of our own growth.”    

Michael Farah, chairman of ERG and Partner at Linden Capital Partners, added, “Dr. Atkinson is a highly regarded Principal Investigator who has built a high quality and incredibly successful practice that is complementary to ERG. FLCR expands ERG’s footprint in growing psychiatric therapeutic areas and provides additional diversification which will allow us to further service our world-wide clients to develop important new therapies.”